Ibrexafungerp Tablets - Uses, Indications, Contraindications, and Side Effects

Overview

A medication called Ibrexafungerp is used to treat or prevent vaginal yeast infections. Yeast often coexists with the body without posing any problems. However, sometimes, it can multiply excessively and result in an infection, particularly in those who are pregnant, diabetic, or on specific medications like hormonal birth control or antibiotics. This medication is an example of an antifungal medication. It functions by inhibiting the growth of yeast and other fungi. The symptoms of vaginal yeast infections, such as discharge that is not normal, itching, pain during sex, or discomfort when urinating, can be lessened by using this medication. The United States Food and Drug Administration (USFDA) approved Ibrexafungerp on June 1, 2021.

Drug Group:

Ibrexafungerp belongs to a group of drugs called antifungals.

Indications:

One kind of vaginal yeast infection is vulvovaginal candidiasis. After adolescence, adult and teenage girls use Ibrexafungerp for two purposes:

• Treating vulvovaginal candidiasis (VVC).

• Reducing the frequency of recurrent vulvovaginal candidiasis (RVVC).

Contraindications:

Ibrexafungerp should not be used by:

• Pregnant women.

• People who are allergic to Ibrexafungerp.

Dosage Forms and Available StrengthsThe purple, oval-shaped Ibrexafungerp tablets are stamped "150" on one side and "SCYX" on the other. They contain 150 mg (milligrams) of Ibrexafungerp.

For Patients

What Is Vulvovaginal Candidiasis?

Vulvovaginal candidiasis (VVC) can be brought on by yeasts or other Candida species; however, Candida albicans is the most common cause. Itching, vaginal soreness, pain during intercourse, discomfort while urinating, and irregular vaginal discharge are common symptoms. However, other illnesses can also cause these symptoms. Approximately 75 percent of women have had VVC at least once, and 40 percent to 45 percent experience it frequently. Symptoms, lab results, individual health considerations, and therapy response are some of the criteria that determine whether a case of VVC is considered simple or difficult. 10 to 20 percent of women may have complex VVC, which calls for a different kind of diagnosis and care.

What Are the Clinical Uses of Ibrexafungerp Tablets?

Ibrexafungerp is a medicine for grown-ups and teenagers to help with vaginal yeast infections. It is also used to prevent these infections from coming back. This medicine belongs to a group of drugs called antifungals. It works by putting a stop to the growth of the fungi that cause the infection.

How Should Ibrexafungerp Tablets Be Used?

Ibrexafungerp is available as an oral tablet. It can be taken with or without food in two doses spaced about 12 hours apart. The patient will be instructed to repeat the daily dosage once a month for six months if Ibrexafungerp is taken to lower the frequency of recurring vaginal yeast infections. It is important to carefully follow the instructions on the prescription label and ask the pharmacist or doctor to clarify any parts one is unsure about. It is important to use Ibrexafungerp exactly as prescribed, that is, without varying the dosage or taking it more frequently than recommended. It is advisable to consult the doctor if symptoms do not get better or worsen.

What Are the Side Effects of Ibrexafungerp Tablets?

Ibrexafungerp may cause side effects. If any of these symptoms are severe or do not go away:

• Diarrhea.

• Nausea.

• Vomiting.

• Stomach pain.

• Dizziness.

Ibrexafungerp may cause other side effects. Call the doctor if there are any unusual problems while taking this medication.

What Are the Things to Inform the Doctor Before Taking Ibrexafungerp Tablets?

• Notify the pharmacist and physician about any allergies the person may have to Ibrexafungerp, other drugs, or any substances in the tablets before starting to take Ibrexafungerp.

• Get the ingredient list from the pharmacist.

• Tell them about any other over-the-counter and prescription drugs, vitamins, supplements, and herbal remedies that one is taking or intends to use.

• Mention prescription drugs like Bosentan, Clarithromycin, Efavirenz, Etravirine, Ketoconazole, Itraconazole, Nefazodone, Nelfinavir, Rifampin, Ritonavir, Saquinavir, or Voriconazole; mention drugs for seizures (sudden, uncontrolled burst of electrical activity between the brain cells) like Carbamazepine, Phenobarbital, or Phenytoin.

• The doctor might have to monitor for adverse effects or change the dosage of medications.

• A lot of other drugs may also interact with Ibrexafungerp; thus, let the doctor know about all of the prescriptions, even ones that are not on this list.

• Additionally, tell the doctor if you use any herbal supplements, particularly St. John's wort (an herbal supplement).

• Please disclose any health issues and whether the patient is pregnant.

• Pregnant women should not be treated with Ibrexafungerp. Before beginning treatment, a pregnancy test must be completed.

• In the event that one becomes pregnant while taking Ibrexafungerp, call the doctor right away.

• Since Ibrexafungerp may harm the fetus, use effective contraception during therapy and for four days following the last dosage.

Dietary Consideration:

Maintain the same diet unless advised otherwise by the doctor.

Missed Dose: If a dose of Ibrexafungerp is missed, take it as soon as possible. However, if it is almost time for the next dose, skip the missed dose and return to the regular dosing schedule. Do not take double doses.

Overdose: If an Ibrexafungerp overdose occurs, contact the poison control helpline. Make an immediate call to emergency services if the person passes out, has a seizure, has difficulty breathing, or is unable to awaken.

Storage: Ibrexafungerp should be kept safely out of children's reach and in its container. It should be kept out of the bathroom and at room temperature, away from sources of heat and moisture.

Disposal: Since many medicine containers are not child-resistant, keep all medications out of children's sight and reach. Prescriptions should always be kept up and away from youngsters, and safety caps should always be locked. Ibrexafungerp should not be flushed down the toilet. Make use of a medicine take-back program to get rid of unnecessary pills. To find out about take-back initiatives in the area, get in touch with the neighborhood recycling or waste agency or pharmacy. If no take-back programs are offered, see the FDA's Safe Disposal of Medicines website for additional information.

For Doctors

Pharmacodynamics:

The pharmacodynamic response to Ibrexafungerp and its exposure-response correlations are not well understood. Regarding cardiac electrophysiology, Ibrexafungerp does not prolong the QTc interval to a clinically significant degree when administered at concentrations five times higher than those obtained following a single day's 300 mg (milligrams) twice-day dose.

Mechanism of Action:

One kind of antifungal drug called Ibrexafungerp functions by preventing the synthesis of 1,3-β-D-glucan, which is necessary for the formation of the fungal cell wall. This drug primarily targets the fungus Candida species, which is frequently implicated in infections. Research indicates that Ibexafungerp is efficacious against Candida species and retains its antifungal properties even in the vaginal acidic environment.

Pharmacokinetics:

• Absorption and Dosage: The body's concentration of Ibrexafungerp increases in healthy individuals in direct proportion to the dosage, be it a single dose ranging from 10 to 1600 mg or several doses ranging from 300 to 800 mg. 300 mg of Ibrexafungerp causes the body to reach particular levels when taken twice a day in two dosages, both while fasting and after eating.

• Peak Levels and Food Effect: Whether administered as a single dose or in several doses, the blood levels of Ibrexafungerp peak four to six hours after oral ingestion of Ibrexafungerp. Eating a high-fat meal with the drug can cause Ibrexafungerp levels in the blood to slightly rise, but this is not considered a clinically relevant alteration.

• Distribution and Elimination: Ibrexafungerp mostly binds to proteins and is found in the bloodstream within the body. Ibrexafungerp is found in vaginal tissue at far larger concentrations in animals than in blood, according to research. Ibrexafungerp is mostly eliminated by the body through metabolism, principally by the enzyme CYP3A4 (Cytochrome P450 3A4), and then excretion through bile. The half-life produced by this technique is roughly 20 hours.

• Excretion: After labeled Ibrexafungerp is taken orally, 90 percent of the radioactive dose is recovered in feces, and just a small amount is eliminated in urine.

What Is the Prescribed Dosage and Method of Administration For Ibrexafungerp Tablets?

• Recommended Dosage:

  • Vaginal Yeast Infections (VVC) Treatment: For one day, administer 300 mg of Ibrexafungerp (two 150 mg tablets) to adult and post-menarchal pediatric girls, spaced about 12 hours apart, i.e., in the morning and evening. Thus, four 150 mg tablets equal 600 mg as the entire daily dosage.

  • Decrease in Recurrent Vaginal Yeast Infections (RVVC) Incidence: Take 300 mg of Ibrexafungerp (two 150 mg tablets) about 12 hours apart, for example., in the morning and evening, for one day to avoid recurrences. For six months, this dosage should be taken once a month.

  • One can take Ibrexafungerp with or without meals.

• Adjusting Dosage With Potent Inhibitors of CYP3A: For one day, take 150 mg of Ibrexafungerp about 12 hours apart (e.g., morning and evening) if the patient is also taking a potent CYP3A inhibitor. If a mild or moderate CYP3A inhibitor is being used, no dosage change is required.

• Assessment of Pregnancy Before Treatment Begins: Before beginning Ibrexafungerp medication, women who are capable of becoming pregnant should confirm that they are not pregnant. To avoid RVVC, recheck pregnancy status before each dose when using Ibrexafungerp once a month for six months.

Clinical Studies:

Ibrexafungerp demonstrated efficacy in treating vaginal yeast infections (VVC) and lowering their recurrence (RVVC) in two clinical trials. The experiment subjects were postmenarchal ladies who were not pregnant. In trial one, conducted in the United States, Ibrexafungerp demonstrated statistically significant outcomes when compared to a placebo. More Ibrexafungerp-treated patients reported total symptom alleviation at both the test of cure (TOC) and follow-up visits. Trial two, which was carried out in both Bulgaria and the United States, also had favorable results. Again, Ibrexafungerp outperformed the placebo in trial three, which examined lowering the incidence of RVVC. Compared to patients on placebo, more Ibrexafungerp-treated patients showed clinical progress at follow-up visits and the test of cure (TOC). These findings imply that Ibrexafungerp is useful in treating VVC, lowering the prevalence of RVVC, providing relief from symptoms, and preventing recurrence.

Drug Interactions:

The enzyme CYP3A4 is responsible for the body's processing of Ibrexafungerp. The amount of Ibrexafungerp in the blood can be altered by other medications that interfere with this enzyme, which may influence the safety and effectiveness of Ibrexafungerp. The following information explains how specific medications impact Ibrexafungerp levels:

• Strong Inhibitors of CYP3A: Medications such as Itraconazole or Ketoconazole can dramatically raise blood levels of Ibrexafungerp. In this situation, the physician might advise lowering the Ibrexafungerp dosage.

• Strong and Moderate Inducers of CYP3A: Drugs such as Carbamazepine, Rifampin, or St. John's Wort may cause Ibrexafungerp levels to drop. It is advisable to avoid taking these medications with Ibrexafungerp since they may reduce its effectiveness.

Since Ibrexafungerp is typically used for a brief period of time to treat vaginal yeast infections, its impact on these systems is not thought to be a concern. However, Ibrexafungerp itself can also disrupt specific enzymes and transporters in the body.

Warnings and Precautions:

• Hazard to Unborn Children:

  • Because it could harm the unborn child, Ibrexafungerp should not be used when pregnant. The active chemical, Ibrexafungerp, was shown in animal experiments to cause birth abnormalities in young rabbits whose mothers took it while pregnant.

  • Before beginning Ibrexafungerp, women who are potentially pregnant should be sure they are not pregnant. If taking Ibrexafungerp once a month for six months to prevent recurrent vaginal yeast infections (RVVC), check again before each dosage.

  • When treating vaginal yeast infections (VVC), women of reproductive age should use an effective birth control method. This should continue for four days after the last dosage of Ibrexafungerp and for the whole six months for RVVC prevention.

Use in Specific Populations:

• Pregnancy: Animal studies have indicated that the unborn child may suffer if Ibrexafungerp is used during pregnancy. According to these investigations, babies born to rabbit mothers who took Ibrexafungerp during pregnancy had birth abnormalities. The effects of Ibrexafungerp on expectant mothers and their unborn children, however, are not well studied. Make sure the woman is not pregnant before beginning Ibrexafungerp. To avoid recurrent vaginal yeast infections (RVVC), if the patient is taking Ibrexafungerp once a month for six months, pregnancy status needs to be verified before each dosage. It is recommended that fertile women utilize an effective birth control method during treating vaginal yeast infections (VVCs) with Ibrexafungerp, as well as for six months following the last dose to prevent VVCs.

• Nursing: It is unknown if Ibrexafungerp enters breast milk, how it affects the infant, or how much milk it produces. Mothers considering Ibrexafungerp should balance the advantages of nursing against the necessity of the medicine and any possible negative effects for the infant.

• Potential Reproductive Females and Males: Ibrexafungerp may be harmful to the fetus if taken during pregnancy, according to research on animals.

• Use in Pediatrics: When treating vaginal yeast infections in post-menarchal (after menstruation begins) pediatric females, Ibrexafungerp is thought to be both safe and efficacious. Additionally, it is used to stop recurring yeast infections in the vagina.

• Use in Geriatrics: If older people react differently to Ibrexafungerp than younger adults, it is unclear from the available data. On the other hand, no appreciable variations were found in the medication-handling practices of older and younger persons.

• Impairment of the Liver: Patients with mild to severe liver disease do not require a change in the Ibrexafungerp dose. It has not, however, been investigated in individuals with serious liver issues.